Drugs / SKB445
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06826040 | Feb 2025 → Dec 2026 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-01-21 | Klus Pharma Inc. | Regulatory Kelun-Biotech’s Novel ADC SKB445 Receives IND Approval from NMPA in China kluspharma.com ↗
the Company has received a clinical trial notice approving the investigational new drug application for the innovative drug SKB445 developed by the Company from the Center for Drug Evaluation of the National Medical Products Administration. |
| 2025-01-21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech’s Novel ADC Drug SKB445 Receives NMPA Approval For the treatment of advanced solid tumors kelun-biotech.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-21 | Klus Pharma Inc. | Kelun-Biotech’s Novel ADC SKB445 Receives IND Approval from NMPA in China kluspharma.com ↗ |
| 2025-01-21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech’s Novel ADC Drug SKB445 Receives NMPA Approval For the treatment of advanced solid tumors kelun-biotech.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB445 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06826040 ↗ |